North America Head and Neck Cancer Market to Grow with a CAGR of 7.37% through 2028
Increase in the incidence of head and neck cancer and
increase in the healthcare investment is expected to drive the North America Head
and Neck Cancer Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “North
America Head and Neck Cancer Market –Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the North
America Head and Neck Cancer Market stood at USD 762.06 million in 2022 and is
anticipated to grow with a CAGR of 7.37% in the forecast period, 2024-2028. The
awareness among individuals regarding Head and Neck Cancer has led to favorable
market conditions for the North America Head and Neck Cancer market. Several
factors contribute to the growth of various Head and Neck Cancer products.
The growing demand for combination therapies in North
America's head and neck cancer market is a response to the need for more
effective, less toxic treatment options. Immunotherapy, targeted therapy,
personalized medicine, ongoing research, and patient advocacy are among the
primary market drivers behind this trend. As we continue to explore innovative
approaches to combat head and neck cancer, it is clear that combination
therapies will play an increasingly critical role in improving patient outcomes
and quality of life.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "North
America Head and Neck Cancer Market.”
The increasing adoption of new treatments in North
America's head and neck cancer market is a response to the urgent need for more
effective and less burdensome treatment options. Immunotherapy, targeted
therapy, personalized medicine, ongoing research, and patient advocacy are
among the primary market drivers fueling this transformative trend. As we
continue to explore innovative approaches to combat head and neck cancer, it is
evident that the integration of novel therapies will play a pivotal role in improving
patient outcomes and enhancing their overall quality of life, which will
further fuel market growth.
In September 2023 - Eli Lilly Canada Inc. announces
the submission of a New Drug Submission (NDS) to Health Canada for Taltz®
(ixekizumab), a humanized monoclonal antibody that inhibits interleukin-17A
(IL-17A), for the treatment of active ankylosing spondylitis (AS).
Increase in the incidence of head and neck cancer.
This alarming trend underscores the pressing need for innovative and effective
treatments. Traditionally, treatment modalities for head and neck cancer
included surgery, radiation therapy, and chemotherapy. While effective to some
extent, these treatments often resulted in severe side effects and reduced
quality of life for patients.
In today's fast-paced world, early detection becomes
even more critical. Patients and healthcare providers should prioritize routine
screenings and regular check-ups to identify potential symptoms or risk factors
for head and neck cancer. Modern advancements in diagnostic tools, such as
high-resolution imaging and non-invasive biopsies, have made early detection
more accessible and efficient. The integration of telemedicine and virtual
consultations has revolutionized cancer care. Patients can now consult with
oncologists and specialists from the comfort of their homes, reducing travel
time and logistical challenges. This not only saves time but also ensures that
patients receive timely medical advice and support, regardless of their
geographical location. In today's fast-paced world, personalized treatment
plans are essential. Genetic profiling and molecular analysis of tumors enable
oncologists to tailor treatment regimens to the unique characteristics of each
patient's cancer. This precision medicine approach ensures that therapies are
both effective and efficient, minimizing unnecessary treatments and side
effects. Clinical trials are essential for advancing cancer care. In a
fast-paced world, access to clinical trials for experimental treatments and
therapies becomes even more critical. Patients should be informed about these
opportunities and encouraged to participate, as they can receive innovative
treatments that may not yet be widely available.
Advances in genetic testing and molecular profiling
have ushered in the era of personalized medicine. By analyzing the genetic
makeup of a patient's tumor, oncologists can tailor treatment regimens to the
unique characteristics of the cancer. This individualized approach has shown
great promise in improving treatment outcomes and minimizing side effects.
In recent times, The most significant risk factor for
head and neck cancer is tobacco use, including cigarettes, cigars, and
smokeless tobacco products. Encouraging individuals to quit smoking through
awareness campaigns and smoking cessation programs is crucial. Excessive
alcohol consumption is another major risk factor for these cancers. Promoting
responsible alcohol consumption and raising awareness about the dangers of
heavy drinking can help prevent head and neck cancer. The human papillomavirus
(HPV) is a significant risk factor for oropharyngeal cancer. In recent times,
HPV vaccination programs targeting adolescents and young adults have been
implemented to prevent HPV-related head and neck cancers. Encouraging
vaccination can reduce the incidence of these cancers. However, Limited Public
Awareness and Education may hinder market growth. Moreover, challenges related
to High Treatment Costs and Healthcare Disparities and Access may pose
obstacles to the Head and Neck Cancer market in the near future.
The North America Head and Neck Cancer Market is
segmented into diagnostics method, treatment type, end-user, regional
distribution, and company.
Based on its diagnostic method, the Biopsy is the most
accurate method for diagnosing head and neck cancer. It involves removing a
small sample of tissue from the affected area and examining it under a
microscope for signs of cancer. Biopsy can be used to diagnose all types of
head and neck cancer, regardless of the location or stage of the disease.
Biopsy is a well-reimbursed procedure by most insurance companies. These
factors are expected to drive the growth of this segment.
Based on region, United States segment is expected to
grow during the forecast period. The United States boasts a
well-established and advanced healthcare infrastructure, including a network of
specialized cancer treatment centers and research institutions. These
institutions are at the forefront of innovation in diagnosing and treating head
and neck cancer. The U.S. is a leader in the development and adoption of
cutting-edge medical technologies, including advanced imaging techniques,
surgical procedures, and therapeutic modalities. This technological advantage
translates into more accurate diagnoses and effective treatments for patients.
The United States is home to numerous pharmaceutical and biotechnology
companies dedicated to oncology research and development. These organizations
continuously invest in discovering new therapies, conducting clinical trials,
and advancing treatment options for head and neck cancer. Patients in the
United States have greater access to clinical trials for experimental treatments
and therapies.
The Canada market is poised to be the fastest-growing
market, offering lucrative growth opportunities for Head and Neck Cancer
players during the forecast period. Factors such as Canada has experienced a
notable increase in the incidence of head and neck cancer in recent years. This
rise in cases has heightened the urgency to enhance diagnosis and treatment
options. Canada has been investing in its healthcare infrastructure, including
cancer treatment centers and research facilities. This investment is expected
to drive advancements in the field. Canada offers universal healthcare
coverage, ensuring that a significant portion of its population has access to
healthcare services, including cancer treatment, without the burden of high
medical expenses. Canadian researchers and institutions actively participate in
international collaborations and clinical trials, contributing to the
development of innovative treatments and therapies. Government initiatives and
policies in Canada focus on improving cancer care and reducing wait times for
diagnosis and treatment, fostering an environment conducive to market growth.
Major companies operating in North America Head
and Neck Cancer Market are:
- Eli Lilly Canada Inc.
- Bristol-Myers Squibb Canada Co.
- Sanofi Canada Inc.
- Pfizer Canada Inc.
- AbbVie Inc.
- Bayer Corporation
- Genentech, Inc.
- Fresenius Medical Care North America
- Sun Pharma North America Inc.
- Teva Pharmaceuticals USA
Download
Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Advancements in Treatment Modalities and
increasing Clinical Trials and Research Initiatives are key drivers of the Head
and Neck Cancer market. In recent years, the growing Immunotherapy drugs,
particularly immune checkpoint inhibitors, have shown promising results in
treating head and neck cancers by harnessing the patient's immune system to
target cancer cells. Moreover, the growing consumer emphasis on preventative
healthcare products has enhanced production and marketing efforts. To meet the
demands of the market, manufacturers are increasingly incorporating
cutting-edge technologies with high production efficiency. Rising consumer
acceptance and continuous product innovation will further ensure the growth of
the Head and Neck Cancer and supplements market in the coming years.,” said Mr.
Karan Chechi, Research Director with TechSci Research, a research-based
management consulting firm.
“North America Head and Neck Cancer Market Segmented
By Diagnostics Method (Biopsy, Imaging, Endoscopy, Others), By Treatment Type
Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By
End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others),
By Country, Competition, Forecast, Opportunity, 2018-2028F”, has evaluated
the future growth potential of North America Head and Neck Cancer Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in North America Head and Neck Cancer Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com